GlassScriptPhysician profile
Diane M Mustafa
NPI 1992088082
$11,437.19
in general payments reported to CMS, 2019-2025
23 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.42 · 2020: $43.93 · 2021: $188 · 2022: $8,021 · 2023: $633 · 2024: $2,136 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,187 · Food and Beverage: $1,078 · Travel and Lodging: $891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,186.99 |
| Food and Beverage | $1,077.92 |
| Travel and Lodging | $891.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $9,531.58 | 2022-2024 | |
| Hologic Sales and Service, LLC | $470.31 | 2021-2025 | Myosure Tissue Removal Device, Acessa Provu System, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Astellas Pharma US INC | $255.97 | 2023-2024 | Veozah |
| Gynesonics, INC. | $147.88 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Cytyc Surgical Products, LLC | $144.12 | 2023 | Acessa Provu System |
| Medtronic, INC. | $136.43 | 2021-2025 | Truclear |
| Abbvie INC. | $117.25 | 2021-2023 | |
| Mayne Pharma Commercial LLC | $92.63 | 2025 | |
| Exeltis, USA INC. | $85.14 | 2023-2025 | Slynd |
| Organon LLC | $67.07 | 2024-2025 | Nexplanon |
| Evofem Biosciences, INC. | $66.10 | 2022-2025 | Phexxi, Solosec, Phexx |
| Ethicon US, LLC | $51.25 | 2025 | Vistaseal, Stratafix |
| Mimedx Group, INC. | $43.90 | 2025 | |
| Merck Sharp & Dohme LLC | $42.93 | 2019-2020 | |
| Lupin INC. | $29.42 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $29.13 | 2024 | |
| Axsome Therapeutics, INC. | $27.64 | 2022 | |
| Kerecis Limited | $21.24 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Sumitomo Pharma America, INC. | $18.05 | 2025 | Myfembree |
| Mycovia Pharmaceuticals, INC. | $16.72 | 2023 | Vivjoa |
| Dysis Medical, INC. | $15.54 | 2022 | |
| Mylan Pharmaceuticals INC. | $13.97 | 2022 | |
| Myovant Sciences INC. | $12.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Mustafa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.